Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

Pharmacodynamic Biomarker Characterization of ALX148, a CD47 Blocker, in Combination with Established Anticancer Antibodies in Patients with Advanced Malignancy

Post navigation

Previous: Discovery of High Affinity, Pan-Allelic, and Pan-Mammalian Reactive Antibodies Against the Myeloid Checkpoint Receptor SIRPα

Next: A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn